146
C.-L. Peng et al. / Dyes and Pigments 84 (2010) 140–147
Porphyrins 3–5 were found to localize in mitochondria, whereas
Porphyrin 2 had less colocalization with MitoTracker Green.
Porphyrin 2 (LD90 w 20 mM) and was less effective in vitro PDT, even
though its cellular uptake and ability for generating singlet oxygen
were high. As the result of confocal imaging, Porphyrin 2 exhibited
more aggregation in the cytosol, and Porphyrin 1 showed a low
fluorescence intensity due to its higher hydrophilicity and conse-
quently for its lower extent of cell uptake.
role in their cellular uptake and photocytotoxicity. In our study,
5,10-di-(N-methyl-4-pyridyl)-15,20-(4-hydroxyphenyl)-21,23H-
porphyrin (Porphyrin 3) showed a higher phototoxicity probably
due to its more specific mitochondrial localization, even though its
cellular uptake and singlet oxygen generating efficiency were not
the best in the series of porphyrin derivatives synthesized. Based on
the results of our study, this organelle-selective porphyrin can be
used as a basis for the synthesis of more compounds with improved
specificity and potency for potential anti-tumor therapy in the
future.
4. Discussion
An ideal photosensitizer should act on novel cellular targets that
are specific for cancer cells and sufficiently different from normal
cells so as to provide a basis for selective tumor cell killing. The
cellular affinity of a photosensitizer is governed by its amphiphilic
character, which is dependent on the regiochemical arrangement of
meso-substituents in the structure. In this study, we investigated
how the modification in the meso-substitution pattern would affect
the properties of porphyrin photosensitizers with the goal of
Acknowledgements
This research was supported by grants from National Science
Council of the Republic of China (NSC 97-2120-M-002-017).
References
developing
selective tumor cell killing.
a novel mitochondria-specific photosensitizer for
[1] Harrod-Kim P. Tumor ablation with photodynamic therapy: introduction to
mechanism and clinical applications. Journal of Vascular and Interventional
Radiology 2006 Sep;17(9):1441–8.
Amphiphilicity is also important because it can affect cellular
uptake and the degree to which the photosensitizer aggregates,
which, in turn, can affect its photophysical properties [30]. It is well
known that the photophysical properties of tetrapyrrole photosen-
sitizer (PS) are strongly affected by their aggregation state [20]. It is
also generally accepted that aggregated PS are less photoactive, i.e.,
theyare lessfluorescent, generate lesssingletoxygen insolution, and
produce less triplet-state PS as determined by laser flash photolysis
[31]. Comparing the partition coefficient values of porphyrin deriv-
atives (Table 1), we found best cellular uptake and photodynamic
efficiency occurred with a partition coefficient (log p) ranging from
about 0.55 to 1.29 in this series of porphyrin derivatives.
A photosensitizer’s structure, charge and overall lipophilicity
determine how it interacts with itself and its surroundings, which
also influence the site of localization in cells [32]. Margaron
et al.[33] and others [34] have reported that amphiphilic photo-
sensitizers are generally more photodynamically active than
symmetrically hydrophilic or hydrophobic molecules. Besides, too
high partition coefficient may let the porphyrin aggregate in the
culture medium, as a consequence, decreasing its cellular uptake.
However, the porphyrin with high hydrophilicity cannot easily
diffuse across the cell membrane. It was demonstrated that
Porphyrin 1 showed low level of cell uptake explaining its low
cytotoxicity and low photodynamic efficiency.
[2] Lai PS, Lou PJ, Peng CL, Pai CL, Yen WN, Huang MY, et al. Doxorubicin delivery
by polyamidoamine dendrimer conjugation and photochemical internaliza-
tion for cancer therapy. Journal of Controlled Release 2007;122(1):39–46.
[3] Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal
diseases: a clinical update. Endoscopy 2003;35(12):1059–68.
[4] Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous
protoporphyrin. 9. Basic principles and present clinical-experience. Journal of
Photochemistry and Photobiology B – Biology 1990;6(1–2):143–8.
[5] Spikes JD. Porphyrins and related compounds as photodynamic sensitizers.
Annals of the New York Academy of Sciences 1975;244(APR15):496–508.
[6] Ochsner M. Photophysical and photobiological processes in the photodynamic
therapy of tumours. Journal of Photochemistry and Photobiology B – Biology
1997;39(1):1–18.
[7] Zhang GD, Harada A, Nishiyama N, Jiang DL, Koyama H, Aida T, et al. Polyion
complex micelles entrapping cationic dendrimer porphyrin: effective photo-
sensitizer for photodynamic therapy of cancer. In: 11th International sympo-
sium on recent advances in drug delivery systems and CRS winter symposium;
2003 Mar 03–06. Salt Lake City, Utah: Elsevier Science Bv; 2003. p. 141–50.
[8] Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al.
Photodynamic therapy. Journal of the National Cancer Institute
1998;90(12):889–905.
[9] Shieh MJ, Peng CL, Lou PJ, Chiu CH, Tsai TY, Hsu CY, et al. Non-toxic photo-
triggered gene transfection by PAMAM-porphyrin conjugates. Journal of
Controlled Release 2008;129(3):200–6.
[10] Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular
targets and mechanisms. Radiation Research 1998;15(5):S146–56.
[11] Kessel D, Luo Y. Mitochondrial photodamage and PDT-induced apoptosis.
Journal of Photochemistry and Photobiology B – Biology 1998;42(2):89–95.
[12] Morgan J, Oseroff AR. Mitochondria-based photodynamic anti-cancer therapy.
Advanced Drug Delivery Reviews 2001;49(1–2):71–86.
[13] Oleinick NL, Morris RL, Belichenko T. The role of apoptosis in response to
photodynamic therapy: what, where, why, and how. Photochemical
Photobiological Sciences 2002;1(1):1–21.
[14] Yang J, Liu XS, Bhalla K, Kim CN, Ibrado AM, Cai JY, et al. Prevention of
&
Obviously Porphyrins 3–5 were found to localize in mitochon-
dria, whereas Porphyrins 1–2 had less colocalization with Mito-
Tracker Green. Some reports confirmed that the aggregation state
of intracellular photosensitizes affect their localization, with the
more aggregated species tending toward lysosomal localization
[35–37]. In this series, Porphyrin 2 with the higher degree of
aggregation was the less active photosensitizing agent, whereas
Porphyrin 3 that localized in the mitochondria was more effective
in in vitro PDT despite its low cellular uptake. Determination of the
target site of the photosensitizer binding has long been a goal of
PDT research [38]. It has been shown that effective photosensitizers
have very diverse patterns of localization, and it seems to be based
on structure, lipophilicity, charge, and amphiphilicity. The site of
drug localization appears to be an important factor for photody-
namic efficiency, in addition to cellular uptake.
apoptosis by Bcl-2: release of cytochrome
Science 1997;275(5303):1129–32.
c from mitochondria blocked.
[15] Liu XS, Kim CN, Yang J, Jemmerson R, Wang XD. Induction of apoptotic
program in cell-free extracts: requirement for dATP and cytochrome c. Cell
1996;86(1):147–57.
[16] Jou MJ, Jou SB, Chen HM, Lin CH, Peng TI. Critical role of mitochondrial reactive
oxygen species formation in visible laser irradiation-induced apoptosis in rat
brain astrocytes (RBA-1). Journal of Biomedical Science 2002;9(6):507–16.
[17] Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharma-
cological Reviews 2002;54(1):101–27.
[18] Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human
cancer. Current Molecular Medicine 2007;7(1):121–31.
[19] Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Elsevier
Sci Ltd; 2004. pp. 755–62.
[20] Kessel D. Hematoporphyrin and hpd – photophysics, photochemistry and
phototherapy. Photochemistry and Photobiology 1984;39(6):851–9.
[21] Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensi-
tizers for use in photodynamic therapy. Journal of Medicinal Chemistry
2004;47(16):3897–915.
[22] Brown SB, Brown EA, Walker I. The present and future role of photodynamic
therapy in cancer treatment. Lancet Oncology 2004;5(8):497–508.
[23] Huang Z. A review of progress in clinical photodynamic therapy. Technology in
Cancer Research & Treatment 2005;4(3):283–93.
5. Conclusions
In summary, many key factors such as lipophilicity, asymmetric
structure and subcellular localization of photosensitizers play a key